Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 6, 2013 (13 years ago)

No Doz

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective container: products are packaged in pouches which may not have been fully sealed

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

No Doz, Max Strength (200 mg caffeine) caplets, 2-count caplets per pouch, Distributed by Novartis Consumer Health, Inc., Parsippany, NJ, NDC 0067 2070 02

Drug: Caffeine

Recalling firm
Novartis Consumer Health
Origin
NE, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-845-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Caffeine recalls

See all
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026
Class I · High risk

Healthy Living Acetaminophen

Labeling: Missing Label - some bottles are missing the the manufacturers label that includes the drug facts information.

Ongoing Labeling / mix-up Aurobindo Pharma USA Inc NDC 58602-882-21 D-0641-2024
Class II · Moderate risk

Migrenol Caplet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-565-00 D-0547-2022

Other recalls by Novartis Consumer Health

All 2013 recalls
Class III · Low risk

Loratadine

Failed Tablet/Capsule Specifications: The products are being recalled due to chipped and broken tablets.

Terminated Failed specification Novartis Consumer Health D-022-2014